Biorasi’s Kurt Gehlsen Appointed to COVID-19 Rapid Response Panel

Aventura, FL (April 24, 2020) – Biorasi is proud to announce that our own Dr. Kurt Gehlsen – Chief Scientific Officer and Vice President of Medical and Scientific Affairs – has been appointed to the COVID-19 Rapid Response Funding panel at Science Foundation Ireland (SFI). Dr. Gehlsen will be part of a task force of international experts that will review applications for funding for “innovative solutions that can have a rapid demonstrable impact on the current COVID-19 crisis in Ireland.”

Working Together for a Solution

“Since the pandemic began, Biorasi has been collaborating with leaders across the healthcare industry to support crisis recovery efforts,” notes Dr. Gehlsen, who has been working with SFI since 2016. “In this capacity, we have leveraged the experience of our leadership and the clinical trial expertise of our company to inform strategies for the research and containment of COVID-19.”

The Rapid Response Panel is part of SFI’s contribution to the Irish Government’s National Action Plan in response to COVID-19. SFI’s mission is that research and innovation have a significant role to play in the national and global response to the healthcare crisis.

SFI’s vision is for Ireland to be a global leader in scientific and engineering research, discovery and innovation. SFI supports the best scientific and engineering research while building an awareness of the role, impact, and opportunities science creates. Biorasi applauds the effort of SFI and is honored to be leveraging its own human resources in support of these goals.

The Changing Landscape of Clinical Trials

With SFI and other organizations working toward testing and treatment, it is important to note that current quarantine and social distancing regulations continue to severely impact existing and future clinical trials. As a CRO, Biorasi is working with our sponsors and vendors to ensure that short and long-term tactics for keeping trials on track and on time are available.

“Decentralization and virtual trials are prime strategies for maintaining processes and operations during the pandemic,” says Dr. Gehlsen. “The landscape for clinical trials is changing, and trial sponsors and CROs will need to adapt and innovate. It cannot be ‘business as usual’ going forward.”

About Science Foundation Ireland (SFI)

Science Foundation Ireland (SFI) is the national foundation for investment in research in the areas of science, technology, engineering, and mathematics (STEM) to assist the development and competitiveness of industry, enterprise and employment in Ireland. It also promotes and supports STEM education and engagement to improve awareness and understanding of the value of STEM to society and to support the STEM careers pipeline.

SFI makes grants based upon the merit review of distinguished scientists. SFI also advances co-operative efforts among education, government, and industry that support its fields of emphasis and promotes Ireland’s ensuing achievements around the world.

About Biorasi

Biorasi is a customer-focused, full-service, contract research organization (CRO) that optimizes the design and delivery of clinical trials for its sponsors, powered by our proprietary TALOS™ project management system. Pharmaceutical companies around the globe rely on Biorasi to consistently deliver success in clinical trial programs for rare and orphan disease and other hard to recruit patient populations such as precision medicine, as well as successful clinical trial rescue. Biorasi’s expertise includes a wide range of molecule types, therapeutic areas, and regulatory pathways. Biorasi is a leader in neurology, nephrology, dermatology, oncology, and the emerging digital therapeutics market.

Established in 2002, Biorasi is headquartered in Aventura, FL, with office-based teams around the globe. From its regional presences, Biorasi is able to directly support studies in the Americas, Europe, and APAC. The company has received the coveted CRO Leadership Award from Life Science Leader magazine and has been placed on the INC 500 list of fastest-growing companies in America.

To learn more about Biorasi’s mission and vision, including rare and orphan disease clinical trial project management and logistics, explore our solutions on our website or contact us at info@biorasi.com or (786) 388-0700.